Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Acquisitions (Details Textual)

v3.4.0.3
Note 2 - Acquisitions (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Developed Technology [Member]        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     18 years  
Trade Names [Member]        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     20 years  
Customer Relationships [Member]        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     4 years  
Cliniqa [Member]        
Revenue, Net $ 10,100,000   $ 20,100,000  
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3,400,000   3,700,000  
Amortization of Intangible Assets 700,000   2,000,000  
Fair Value Write-Up of Acquired Inventory 100,000   900,000  
Zephyrus [Member]        
Revenue, Net 0   0  
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 100,000   100,000  
Amortization of Intangible Assets 100,000   100,000  
Revenue, Net 130,973,000 $ 114,158,000 364,261,000 $ 334,583,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 42,490,000 38,759,000 109,711,000 115,920,000
Amortization of Intangible Assets     22,443,000  
Fair Value Write-Up of Acquired Inventory $ 1,082,000 $ 897,000 $ 3,439,000 $ 5,252,000